DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-04 ...

Core Viewpoint - Bioventus Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its innovations in active healing [1] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [2] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [2] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [2]

Core Points - Bioventus Inc. will present at the Piper Sandler Healthcare Conference on December 3, 2025, at 10:10 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Viewpoint - Bioventus Inc. will report its financial results for Q3 of fiscal year 2025 on November 4, 2025, and will host a conference call to discuss these results and provide a business update [1]. Financial Reporting - The financial results will be announced before the market opens on November 4, 2025 [1]. - A conference call is scheduled for 8:30 a.m. Eastern Time on the same day to discuss the results [1]. Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2]. - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until November 3, 2026 [2]. Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that aid in quick and safe healing [3]. - The company's mission focuses on helping patients resume active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3]. - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3].

Core Insights - Bioventus Inc. will participate in the Morgan Stanley Global Healthcare Conference on September 10, 2025, with CFO Mark Singleton speaking [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Insights - Bioventus Inc. is a global leader in innovations for active healing and will have its President and CEO, Rob Claypoole, participate in a fireside chat at the Canaccord Genuity Global Growth Conference on August 12, 2025 [1] - A live webcast of the presentation will be available on the company's website, along with a replay option after the event [2] Company Overview - Bioventus delivers clinically proven and cost-effective products aimed at helping individuals heal quickly and safely, with a mission to assist patients in resuming active lives [3] - The company's offerings include Pain Treatments, Restorative Therapies, and Surgical Solutions, all built on high quality standards and evidence-based medicine [3] - Bioventus is recognized as a trusted partner for physicians globally, emphasizing strong ethical behavior in its operations [3]

Core Viewpoint - Bioventus Inc. has secured a $400 million Senior Secured Credit Agreement, which includes a $300 million term loan and a $100 million revolving credit facility, aimed at enhancing liquidity and financial flexibility [1][2][3]. Group 1: Credit Agreement Details - The new Credit Agreement increases the revolving credit facility from $40 million to $100 million compared to the previous 2019 Credit Agreement [2]. - The interest margin has been reduced by 75 basis points, resulting in over $2 million in annual interest expense savings [2]. - The annual amortization on the term loan has been lowered from 10% to 5% for the duration of the loan [2]. Group 2: Financial Impact and Use of Proceeds - The proceeds from the Credit Agreement were utilized to repay the outstanding loan balance of $333 million under the 2019 Credit Agreement [3]. - The repayment was accomplished using $30 million drawn from the new revolving credit facility, $3 million in cash from the balance sheet, and the new $300 million term loan [3]. Group 3: Company Overview - Bioventus is recognized for delivering clinically proven, cost-effective products that facilitate quick and safe healing, with a mission to help patients resume active lives [4]. - The company focuses on innovations for active healing, including pain treatments, restorative therapies, and surgical solutions [4].

Core Insights - Bioventus Inc. will report its financial results for Q2 of fiscal year 2025 on August 6, 2025, before market opening [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Company Overview - Bioventus is a global leader in innovations for active healing, delivering clinically proven and cost-effective products that aid in quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Viewpoint - Bioventus Inc. will report its financial results for Q1 of fiscal year 2025 on May 6, 2025, before market opening, followed by a conference call for discussion [1] Group 1: Financial Reporting - The financial results for the first quarter of fiscal year 2025 will be announced before the market opens on May 6, 2025 [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Group 2: Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2] - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until May 5, 2026 [2] Group 3: Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products for quick and safe healing [3] - The company's mission focuses on helping patients resume active lives through offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]